Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update

Phase 3 VIKTORIA-1 trial achieved primary endpoint with clinically meaningful improvement in progression-free survival in PIK3CA mutant cohort; detailed data for gedatolisib regimens will be presented ...
TCTMD

Subcutaneous Furosemide Aids With Earlier Discharge: SUBCUT II HF

Patients were safely able to return home and receive the diuretic by minipump, minimizing their time spent at the hospital.

Nanoform Finland Oyj: Inside information: Nanoform Signs First Exclusivity Agreement for Ultra-High Concentration Subcutaneous Delivery

May 12, 2026 at 08:00:00 EEST Helsinki, Finland - Nanoform Finland Plc ("Nanoform"), the medicine performance-enhancing company, today announced that it has ...
Healio

FDA grants fast track designation to intra-articular GLP-1 analog for knee osteoarthritis

The FDA has granted fast track designation to 4P004, a GLP-1 agonist analog, for the treatment of knee osteoarthritis, ...

Roche launches subcutaneous lung cancer immunotherapy, cuts delivery time to 7 min

Roche launched Tecentriq SC in India, reducing lung cancer immunotherapy delivery time from hours to just seven minutes.